Edition:
United States

Biogaia AB (BIOGb.ST)

BIOGb.ST on Stockholm Stock Exchange

357.00SEK
28 Apr 2017
Change (% chg)

12.50kr (+3.63%)
Prev Close
344.50kr
Open
351.50kr
Day's High
362.50kr
Day's Low
350.50kr
Volume
40,010
Avg. Vol
22,897
52-wk High
362.50kr
52-wk Low
200.00kr

Latest Key Developments (Source: Significant Developments)

ADDvise receives order from subsidiary to BioGaia worth SEK 2.1 mln
Monday, 3 Apr 2017 07:25am EDT 

ADDVISE GROUP AB (PUBL) : ADDVISE RECEIVES ORDER FROM A SUBSIDIARY TO BIOGAIA WORTH 2,1 MSEK .ORDER IS WORTH APPROXIMATELY 2,1 MSEK AND WILL BE DELIVERED DURING SECOND AND Q3 OF 2017.  Full Article

Biogaia says signs exclusive agreement in Australia
Thursday, 16 Mar 2017 05:00am EDT 

Biogaia Ab : Biogaia signs exclusive agreement in Australia .BioGaia has extended its global collaboration with Nestlé by signing an agreement with Nestlé Australia Ltd for the exclusive rights to sell BioGaia Protectis drops in Australia from 2017.  Full Article

Biogaia signs major distribution and license agreements with partner in Japan
Monday, 5 Dec 2016 02:04am EST 

Biogaia Ab : Biogaia signs major distribution and license agreements with partner in japan . Through its Japanese subsidiary BioGaia has signed two new exclusive distributor agreements for Japan with Nippon Kabaya Ohayo Holdings Inc. One for sales of finished probiotic supplements with Lactobacillus reuteri and one for use of Lactobacillus reuteri as ingredient in food . Launches are planned to 2017 Further company coverage: [BIOGb.ST].  Full Article

Biogaia says Q2 net sales rose to SEK 136.0 mln
Wednesday, 17 Aug 2016 02:00am EDT 

Biogaia says: Q2 net sales amounted to SEK 136.0 million (134.0). . Q2 Net sales in Business Unit Paediatrics reached SEK 106.7 million (108.8). . Q2 operating profit excluding IBT was sek 53.4 million (48.4) and including IBT, operdating profit was SEK 53.4 million. . Profit after tax excluding IBT was SEK 38.6 million (40.4) .Second quarter earnings were driven by very strong sales in Europe where the Easy Dropper launch continues, strong sales in Asia and modest sales in the USA and Canada..  Full Article

Biogaia Q1 operating profit falls
Tuesday, 10 May 2016 02:00am EDT 

Biogaia Q1 : Operating profit was SEK 46.1 million (52.6) .Q1 net sales amounted to SEK 133.9 million (138.8).  Full Article

BioGaia says oral health probiotics to be launched in Hong Kong
Monday, 25 Apr 2016 03:00am EDT 

BioGaia AB:Has signed an agreement with BioWellTech Co Ltd for the rights to sell BioGaia ProDentis in Hong Kong.The launch is planned to take place during Q3.  Full Article

BioGaia AB says analysis confirms effectiveness of BioGaia ProDentis in periodontitis
Friday, 18 Mar 2016 04:00am EDT 

BioGaia AB:Says meta-analysis confirms effectiveness of Biogaia prodentis in periodontitis.  Full Article

BioGaia to distribute and list IBT subsidiary
Friday, 12 Feb 2016 02:00am EST 

BioGaia AB:Says ‍proposes distribution and separate listing of Infant Bacterial Therapeutics (IBT) subsidiary.To finance IBT's first clinical trial, company has capital need of around 100 mln Swedish crown.Capital need planned to be raised through a rights issue in Q2 with preferential rights for IBT's shareholders.March 29 set to be first day of trading in IBT's shares on Nasdaq First North​.  Full Article

BioGaia plans to distribute total dividend of SEK 5.00 per share​
Thursday, 11 Feb 2016 07:00pm EST 

BioGaia AB:Says ‍board proposes dividend of 3.03 Swedish crowns per share to be paid for 2015.Additionally, proposes extraordinary dividend of 1.97 crowns per share.Plans to distribute total oftotal dividend of SEK 5.00 per share.​.  Full Article

BioGaia AB subsidiary closer to FDA approval for clinical studies
Friday, 8 Jan 2016 08:00am EST 

BioGaia AB:Says subsidiary IBT has U.S. IND open and Swedish CTA approved for clinical study.Infant Bacterial Therapeutics (IBT), a subsidiary of BioGaia, announced that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by FDA (the U.S. Food and Drug Administration).Furthermore, IBT has received approval from the MPA (Medical Product Agency) to conduct its clinical trial in Sweden.IBT has an open IND accepted by the FDA, which is an important step in allowing IBT to start clinical studies in the U.S.  Full Article

More From Around the Web